Orforglipron is Eli Lilly's small-molecule, non-peptide GLP-1 receptor agonist — the first true oral GLP-1 cleared for obesity, branded as Foundayo. Unlike semaglutide and tirzepatide, orforglipron requires no fatty-acid modification and no peptide-stabilizing matrix to survive the gut. The molecule is primarily hepatically metabolized; the label warns against use in severe hepatic impairment, but mild-to-moderate liver impairment is allowed at the standard dose.
The ACHIEVE Phase 3 program covered type-2 diabetes (ACHIEVE-1, ACHIEVE-2), obesity (ACHIEVE-3, ACHIEVE-4), and adjacent indications. The FDA approved the obesity indication in April 2026. Indirect comparisons against oral semaglutide and oral Wegovy have been mixed: orforglipron leads on HbA1c, oral semaglutide may lead on weight loss. By the April 30 Q1 2026 call, roughly 20,000 patients were on the drug, more than 8,000 prescribers had written it, and Lilly confirmed commercial access at two of the three largest US PBMs effective mid-May. On May 4, an FAERS hepatic-failure case logged April 30 surfaced publicly — Lilly's Global Patient Safety team called the event 'not reasonably related to Foundayo,' and the company released updated safety data the FDA had requested, citing no DILI signal across the 11,000-patient ACHIEVE+ATTAIN program.
The small-molecule approach carries pricing and manufacturing implications the peptide GLP-1 economy does not — CDMO capacity stops being the bottleneck, and small-molecule generics will eventually follow a different cost curve. Stories here cover trial readouts, post-launch tracking, and competing oral programs.
IQVIA's weekly prescription tracker for Foundayo (orforglipron) hit approximately 17,000 prescriptions for the week ending May 15, 2026, per Citi's Friday client note — Lilly's first above-15,000 weekly print since the April 6 launch. The week-by-week trajectory: 1,390 (Week 1), 3,707 (Week 2), 5,612 (Week 3), 7,335 (Week 4), 10,248 (Week 5), and ~17,000 in the new print. Novo Nordisk's Wegovy pill recorded roughly 142,000 prescriptions in the same week — the trajectory gap is narrowing as Foundayo's PBM coverage activates at the largest US plans but still remains 8.3x the Foundayo volume. Citi maintains $146M Foundayo Q2 revenue and $1.6B 2026 full-year estimates; the IQVIA print supports the trajectory. Lilly's late-May TV-advertising launch may amplify the next leg of Foundayo growth heading into mid-June.
The CNBC May 18 piece surfaced explicit company-supported positioning that Foundayo (orforglipron) and oral Wegovy are targeting different patient segments rather than competing head-to-head. Novo's framing for Wegovy pill is 'injectable-like efficacy' in oral form, with the Phase 3 OASIS-MAINTAIN data anchoring approximately 15% mean weight loss. Lilly's framing for Foundayo positions it as more of a 'starter' GLP-1 — lower weight-loss ceiling (around 11.2% in ATTAIN-1) but no food-or-water dosing restrictions and a non-peptide small-molecule manufacturing path that supports a lower long-term price. Both companies say the pills are expanding the market rather than significantly cannibalizing demand for the injectables — a different framing than the 'oral-disrupts-injectable' narrative that dominated 2025 coverage. The market-expansion hypothesis will be testable as ADA 2026 (June 5-8) and Q2 2026 earnings prints land.
Eli Lilly executives confirmed on the April 30 Q1 call that a full direct-to-consumer TV advertising campaign for Foundayo (orforglipron) launches in late May 2026, coinciding with the mid-May commercial access activation at two of the three largest US pharmacy benefit managers. The campaign emphasizes Foundayo's only-oral-GLP-1-without-food-or-water-restrictions positioning vs Novo's Wegovy pill, which requires fasting administration. Lilly previously held back consumer advertising through the first six weeks of launch to let PBM coverage scale before driving consumer prescription demand. Citi's May 8 IQVIA note flagged the upcoming campaign and PBM expansion as the catalysts for the Week 5+ trajectory acceleration that landed in the May 8 IQVIA print (10,248 scripts, +40% w/w).
Citi's Friday May 15 client note reported Foundayo (orforglipron) hit 10,248 US prescriptions in the week ending May 8 per IQVIA — the first 40% week-over-week jump in the launch series. Week-by-week trajectory: 1,390 (Week 1), 3,707 (Week 2), 5,612 (Week 3), 7,335 (Week 4), 10,248 (Week 5). The acceleration aligns with mid-May commercial access activation at two of the three largest US PBMs that Lilly flagged on the April 30 Q1 call. Citi maintained $146M Q2 revenue and $1.6B full-year 2026 estimates. The Wegovy pill remains ahead — Novo CEO Doustdar's May 14 commentary confirmed >1M cumulative US users since the January 5 launch — but the gap is narrowing as Foundayo's PBM coverage comes online and telehealth volume (~35% of total per Lilly executives, not captured in retail-only IQVIA data) layers on top.
The next Foundayo IQVIA prescription tracker update is expected from Citi mid-week May 18-20, covering the week ending May 8. Week 4 hit 7,335 prescriptions per the May 8 Citi note with Lilly executives citing 20,000 total patients (~35% via telehealth not captured in the retail-only IQVIA data). Citi's projected $146M Q2 revenue and $1.6B full-year 2026 estimate continue to anchor the analyst consensus. Lilly executives have asked analysts for 8-12 weeks of data before reading commercial trajectory through pharmacy-fill noise; the Week 5 reading is the first post-PBM-coverage-expansion data point as the two largest US PBMs went live with Foundayo coverage mid-May. The Wegovy pill remains roughly 60-70x ahead on weekly volume (>440K in the week ending May 1 per Novo's Q1 commentary).
Eli Lilly published SURMOUNT-MAINTAIN in The Lancet and ATTAIN-MAINTAIN in Nature Medicine on May 12, with concurrent presentation at ECO 2026 in Istanbul. SURMOUNT-MAINTAIN tested lower-dose Zepbound (tirzepatide 5 mg) vs maximum tolerated dose: at week 112, MTD preserved all weight loss while the 5 mg arm lost only 5.6 kg additional. ATTAIN-MAINTAIN tested Foundayo (orforglipron) as a switch from injectable GLP-1s in SURMOUNT-5 participants: orforglipron preserved 79.3% of injectable-phase weight loss vs 37.6% on placebo at week 52; Wegovy MTD switchers regained only 0.9 kg, Zepbound MTD switchers regained 5.0 kg. The dual readout reframes the maintenance-versus-discontinuation conversation: dose-tapering and oral-switching strategies now have Phase 3 evidence behind them, validating the long-term-treatment chronic-disease framing.
An ORION indirect treatment comparison presented at ECO 2026 on May 13 framed the head-to-head competition between Novo's Wegovy pill (oral semaglutide 25 mg) and Lilly's Foundayo (orforglipron 36 mg). The Wegovy pill delivered statistically significant greater mean weight loss than orforglipron, with patients on orforglipron showing approximately 14x higher odds of discontinuing treatment due to gastrointestinal side effects. The May 13 framing complements Novo's Q1 print disclosure that Wegovy holds 65% of all new US GLP-1 prescriptions; CEO Mike Doustdar's CNBC commentary called the moment a 'turnaround situation' for the Danish company. The ORION ITC matters as a prescriber-decision tool given the two compounds are now the only two FDA-approved oral GLP-1s for chronic weight management.
Eli Lilly's Foundayo (orforglipron) reached UAE pharmacies on May 12 in Abu Dhabi, expanding from the April Dubai launch. The Emirates Drug Establishment first approved Foundayo on April 3, making the UAE the second country globally to register the once-daily oral GLP-1 pill. Pricing runs from AED 773/month for the 0.8 mg starter dose to AED 1,599/month for the 17.2 mg highest dose. Abu Dhabi has folded Foundayo into the emirate's broader weight-loss program, signaling government coverage rather than purely self-pay. The launch is one of the first international rollouts since FDA approval April 1; Lilly executives have framed UAE prescribing patterns and patient adherence as an early read on geriatric and Middle East regional patient response.
A Nature paper published May 6 from a University of Virginia team developed humanized GLP1R mouse models to investigate how small-molecule GLP1R agonists — including orforglipron (Foundayo) — regulate feeding behavior. Beyond canonical hypothalamic and hindbrain networks that control metabolic homeostasis, the team showed these oral compounds recruit a discrete population of Glp1r-expressing neurons in the central amygdala and selectively suppress consumption of palatable foods by reducing dopamine release in the nucleus accumbens — a parallel hedonic-feeding circuit distinct from the homeostatic mechanism that drives most GLP-1 weight loss. The work explains why patients on small-molecule oral GLP-1s often report reduced food cravings and pleasure-driven eating, and identifies a neural circuit with implications for substance-use disorder and binge eating beyond obesity.
A post-hoc subgroup analysis of Eli Lilly's orforglipron (Foundayo) in adults aged 65 and older, drawn from the ATTAIN-1 and ATTAIN-2 Phase 3 programs, will be presented at ECO 2026 in Istanbul May 12-15. The analysis pools 616 randomized participants (613 treated) — 118 on 6 mg, 135 on 12 mg, 146 on 36 mg orforglipron, and 214 placebo — across patients with and without type 2 diabetes. The geriatric data set addresses a long-standing clinical gap: incretin trials have systematically underenrolled adults over 65, the population most affected by obesity-related comorbidities and the most likely to face polypharmacy-related GI tolerability concerns. Lead author Dr. Deborah Horn (UTHealth Houston McGovern Medical School). The presentation is among the ECO 2026 abstracts that will shape geriatric prescribing patterns for the first FDA-approved GLP-1 pill that does not require fasting or water restrictions.
In its fourth commercial week (April 27–May 1), Eli Lilly's Foundayo (orforglipron) recorded 7,335 prescriptions per IQVIA, Citi told clients May 8, calling the early launch 'off to a solid start' and modeling $146M in Q2 revenue and $1.6B for full-year 2026. Citi flagged that IQVIA captures retail and partial telehealth data but likely understates Lilly Direct and the 12+ telehealth firms representing roughly 35% of launch volume; Lilly executives have cited 20,000 patients now on Foundayo. For comparison, Citi's same note pegged Wegovy pill at 440,410 prescriptions in the week ending May 1, with oral semaglutide accounting for 33% of all Novo obesity referrals.
An FDA Adverse Event Reporting System (FAERS) entry logged April 30 surfaced publicly May 4, documenting hepatic failure in a 56-year-old male patient on Foundayo (orforglipron). The case was marked for expedited review and could have occurred at or before April 15 — Foundayo only launched April 9. There have been 34 total Foundayo FAERS reports so far, with two considered serious. LLY traded down nearly 3% premarket — hitting roughly $936 — before recovering on Lilly's response. Foundayo's label carries a warning that the medication is 'not recommended for use in patients with severe hepatic impairment' (orforglipron is primarily hepatically metabolized), but mild and moderate liver impairment is allowed at standard dose.
On the April 30 call, Lilly USA executive Ilya Yuffa said roughly 20,000 patients are now on Foundayo (orforglipron) for obesity or overweight and more than 8,000 prescribers have written it. Notably, 80% of patients are new to the GLP-1 class and one-third of prescribers had not previously written an oral GLP-1, suggesting Foundayo is expanding the addressable market rather than purely cannibalizing injectables. Lilly also confirmed commercial access at two of the three largest U.S. pharmacy benefit managers effective mid-May. Active sales-force promotion only began the week of April 23, two weeks after broad supply-channel availability on April 9.
Fierce Pharma's Oral GLP-1 Tracker reported May 1 that Eli Lilly's Foundayo (orforglipron) reached 5,612 prescriptions in the week ending April 24 — its third full commercial week — up roughly 51% from Week 2's 3,707 scripts but still behind the Wegovy pill's comparable third-week run. RBC and other analysts continue to caution that 8–12 weeks of data are needed to read commercial trajectory through pharmacy-fill noise. On the Q1 earnings call, Lilly USA's Ilya Yuffa said roughly 20,000 patients are now on the drug for obesity or overweight, calling the early launch 'encouraging.'
Eli Lilly shares fell April 24 after the latest weekly prescription data for Foundayo showed 3,707 scripts for the week ending April 17 — behind analyst expectations. For comparison, Novo's Wegovy pill reached 18,410 prescriptions in its second week after a January launch. RBC Capital Markets analyst Trung Huynh said early comparisons should be viewed cautiously but acknowledged the uptake is 'likely to be received negatively.' Fierce Pharma launched a weekly Oral GLP-1 Tracker to follow Foundayo and Wegovy pill head-to-head.
IQVIA tracking data reported April 21 showed Eli Lilly's newly-launched oral GLP-1 Foundayo (orforglipron) drew 1,390 prescriptions in its first full week (April 6-10), roughly 45% of the 3,071 Wegovy pill scripts in Novo Nordisk's launch week in January. Analyst consensus requires Foundayo to hit about 5.4 million prescriptions from April-December to generate $1.7 billion in 2026 revenue — a target that looks challenging at the current trajectory.
Eli Lilly announced positive topline results from ACHIEVE-4, the longest Phase 3 study of Foundayo (orforglipron) to date in 2,700+ adults with type 2 diabetes across 15 countries. The pre-planned analysis showed a 57% lower risk of all-cause death (HR 0.43, p=0.002), while meeting non-inferiority for the prespecified cardiovascular endpoint (HR 0.84). Lilly plans to submit Foundayo for type 2 diabetes to the FDA by end of Q2.
BioSpace analysis frames the ACHIEVE-4 results as a direct answer to the FDA's April 1 letter requesting post-market liver injury and cardiovascular data. The 'outstanding' type 2 diabetes data, combined with cardiovascular safety and all-cause death reductions, strengthens Lilly's position ahead of its Q2 FDA submission and could reduce regulatory friction for the oral GLP-1 franchise.